

Cancer Endorsement Maintenance Phase II

Voting Webinar



NATIONAL
QUALITY FORUM

August 14, 2012

Webinar Goals

- Provides opportunity for clarification and questions prior to voting, including reviewing:
 - Project scope
 - Measures recommended for endorsement
 - Overarching issues
 - Summary of comments and responses

Project Scope

- 44 measures will be reviewed in the project over two phases
 - The measures address the following topic areas:

Phase 1:

- Hematology
- Melanoma
- Prostate cancer
- Palliative care for cancer patients at the end of life
- Medical and radiation oncology
- Lung cancer

Phase 2:

- Colorectal cancer
- Breast cancer

Measures Recommended-Phase 2

	MAINTENANCE	NEW	TOTAL
Measures under consideration	15	6*	21
Withdrawn from consideration	3	0	3
Recommended	10	6	16
Not recommended	2	0	2
Reasons for Not Recommending	Importance – 2	N/A	

*Includes 1 untested measures eligible for [time-limited endorsement](#).


Comments

- Phase 2:
 - There were 39 comments received on the phase 1 draft report from 7 member organizations.

- Comment themes:
 - The comments overall were largely supportive of the Steering Committee recommendations for endorsement.
 - Recommendations relating to measure 0031: Breast Cancer Screening (NCQA)
 - Request for harmonization and combination of measures 1859: KRAS gene mutation testing performed for patients with metastatic colorectal cancer who receive anti-epidermal growth factor receptor monoclonal antibody therapy and 1860: Patients with metastatic colorectal cancer and KRAS gene mutation spared treatment with anti-epidermal growth factor receptor monoclonal antibodies
 - Measure Gaps

Impact of Comments

- Recommendations relating to measure 0031: Breast Cancer Screening (NCQA)
 - Measure 0031 was not recommended for endorsement, as the evidence supporting the measure is inconsistent.
- Request for harmonization and combination of measures 1859: and 1860
 - The measures were not combined, as they address different points in the process of care. The measures are from the same developer and were already harmonized.
- Measure Gaps
 - Additional measure gap areas were added to the report.



Questions??